HFA Premium Access

Welcome and introductions - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Topic: Diabetes and the Heart
Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Presentation

About the speaker

Professor Alexandre Mebazaa

Hospital Lariboisiere, Paris (France)
53 presentations
2 followers

5 more presentations in this session

What have cardiovascular outcomes trials taught us about cardiovascular risk management?

Speaker: Professor M. Pfeffer (Boston, US)

Thumbnail

Emerging knowledge on cardiorenal protection.

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

From classroom to clinic: sodium–glucose co-transporter 2 inhibitor evidence in practice.

Speaker: Professor S. Verma (Toronto, CA) Professor M. Cowie (London, GB) Doctor S. Wiviott (Boston, US) Professor A. Mebazaa (Paris, FR)

Thumbnail

What we still need to learn from sodium–glucose co-transporter 2 inhibitors to predict the future.

Speaker: Professor M. Cowie (London, GB)

Thumbnail

Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Speaker: Professor S. Verma (Toronto, CA) Professor M. Cowie (London, GB) Professor A. Mebazaa (Paris, FR) Professor M. Pfeffer (Boston, US)

Thumbnail

Access the full session

Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)

Speakers: Professor A. Mebazaa, Professor M. Pfeffer, Professor S. Verma, Professor S. Verma, Professor M. Cowie...
Thumbnail

About the event

Image

Heart Failure 2019 - 6th World Congress on Acute Heart Failure

25 May - 28 May 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk